Inhibition of mTOR Activity Restores Tamoxifen Response in Breast Cancer Cells with Aberrant Akt Activity
暂无分享,去创建一个
Manuel Hidalgo | Richard A. Roth | W. Friedrichs | M. Hidalgo | R. Roth | L. Degraffenried | Jessica M. Silva | Elissa J. Donzis | Linda A. deGraffenried | William E. Friedrichs | Douglas H. Russell | Amanda K. Middleton | D. Russell | A. Middleton | E. Donzis | Linda A. Degraffenried
[1] Kenneth M. Yamada,et al. Laminin-10/11 and Fibronectin Differentially Prevent Apoptosis Induced by Serum Removal via Phosphatidylinositol 3-Kinase/Akt- and MEK1/ERK-dependent Pathways* , 2002, The Journal of Biological Chemistry.
[2] S. Lowe,et al. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy , 2004, Nature.
[3] A. Howell,et al. Tamoxifen ("Nolvadex"): a review. , 2002, Cancer treatment reviews.
[4] W. Friedrichs,et al. Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells. , 2002, Cancer research.
[5] P. Chambon,et al. Modulation of transcriptional activation by ligand‐dependent phosphorylation of the human oestrogen receptor A/B region. , 1993, The EMBO journal.
[6] R. Lupu,et al. The significance of heregulin in breast cancer tumor progression and drug resistance. , 1996, Breast cancer research and treatment.
[7] Brett L Carlson,et al. Inhibition of the mammalian target of rapamycin sensitizes U87 xenografts to fractionated radiation therapy. , 2002, Cancer research.
[8] R. Cardiff,et al. Activation of Akt (Protein Kinase B) in Mammary Epithelium Provides a Critical Cell Survival Signal Required for Tumor Progression , 2001, Molecular and Cellular Biology.
[9] H. Kurokawa,et al. ErbB (HER) receptors can abrogate antiestrogen action in human breast cancer by multiple signaling mechanisms. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[10] A. Gingras,et al. 4E-BP1, a repressor of mRNA translation, is phosphorylated and inactivated by the Akt(PKB) signaling pathway. , 1998, Genes & development.
[11] Shile Huang,et al. Sustained activation of the JNK cascade and rapamycin-induced apoptosis are suppressed by p53/p21(Cip1). , 2003, Molecular cell.
[12] P. Dennis,et al. Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. , 2002, Molecular cancer therapeutics.
[13] P. Vogt,et al. A role of the kinase mTOR in cellular transformation induced by the oncoproteins P3k and Akt. , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[14] Hong Wu,et al. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[15] T. Franke. Assays for Akt. , 2000, Methods in enzymology.
[16] Gordon B Mills,et al. Targeting the Phosphatidylinositol 3-Kinase / Akt Pathway for Enhancing Breast Cancer Cells to Radiotherapy 1 , 2003 .
[17] Simak Ali,et al. Phosphatidylinositol 3-Kinase/AKT-mediated Activation of Estrogen Receptor α , 2001, The Journal of Biological Chemistry.
[18] M. Hidalgo,et al. The rapamycin-sensitive signal transduction pathway as a target for cancer therapy , 2000, Oncogene.
[19] Christine C. Hudson,et al. Regulation of Hypoxia-Inducible Factor 1α Expression and Function by the Mammalian Target of Rapamycin , 2002, Molecular and Cellular Biology.
[20] R. Roth,et al. Evidence of insulin-stimulated phosphorylation and activation of the mammalian target of rapamycin mediated by a protein kinase B signaling pathway. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[21] N. Weigel,et al. Ligand-independent activation of steroid hormone receptors , 1998, Journal of Molecular Medicine.
[22] M. Hung,et al. Akt activation by estrogen in estrogen receptor-negative breast cancer cells. , 2001, Cancer research.
[23] W. Friedrichs,et al. Reduced PTEN expression in breast cancer cells confers susceptibility to inhibitors of the PI3 kinase/Akt pathway. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.
[24] R. Roth,et al. Akt, a Pleckstrin Homology Domain Containing Kinase, Is Activated Primarily by Phosphorylation* , 1996, The Journal of Biological Chemistry.
[25] B. Katzenellenbogen,et al. Printed in U.S.A. Copyright © 2000 by The Endocrine Society A Role for Akt in Mediating the Estrogenic Functions of Epidermal Growth Factor and Insulin-Like Growth Factor I* , 2000 .
[26] M. Dowsett,et al. Towards a molecular basis for tamoxifen resistance in breast cancer. , 1992, Annals of oncology : official journal of the European Society for Medical Oncology.
[27] H. Moses,et al. Rapamycin Potentiates Transforming Growth Factor β-Induced Growth Arrest in Nontransformed, Oncogene-Transformed, and Human Cancer Cells , 2002, Molecular and Cellular Biology.
[28] K. M. Nicholson,et al. The protein kinase B/Akt signalling pathway in human malignancy. , 2002, Cellular signalling.
[29] J. Blenis,et al. An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/− mice , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[30] M. West,et al. Translational induction of the c-myc oncogene via activation of the FRAP/TOR signalling pathway , 1998, Oncogene.